PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
This story is reported by Nature. Read what other outlets are saying below, then open the original report for full details.